SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2176868

Cover Image

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2176868

Rapid Tests

PUBLISHED:
PAGES: 479 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Team License: Up to 10 users)
USD 11115
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Global Rapid Tests Market to Reach US$16.6 Billion by 2032

The global market for Rapid Tests estimated at US$12.4 Billion in the year 2025, is expected to reach US$16.6 Billion by 2032, growing at a CAGR of 4.3% over the analysis period 2025-2032. Instruments Offering, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$6.4 Billion by the end of the analysis period. Growth in the Consumables Offering segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.4 Billion While China is Forecast to Grow at 7.3% CAGR

The Rapid Tests market in the U.S. is estimated at US$3.4 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2032 trailing a CAGR of 7.3% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Rapid Tests Market - Key Trends and Drivers Summarized

How Are Rapid Tests Revolutionizing Healthcare Diagnostics?

Rapid tests have become a cornerstone of modern healthcare diagnostics, offering quick and accurate results that enable timely decision-making and treatment. These tests are designed to detect the presence of specific pathogens, biomarkers, or antibodies in a matter of minutes to hours, making them invaluable tools in clinical settings, particularly in situations where immediate results are crucial. Rapid tests are widely used for diagnosing infectious diseases such as COVID-19, influenza, HIV, and malaria, as well as for monitoring chronic conditions like diabetes and cardiovascular diseases. The convenience and speed of rapid tests allow healthcare providers to quickly assess a patient's condition, initiate appropriate treatment, and prevent the spread of infectious diseases. As healthcare systems increasingly prioritize efficiency and patient-centered care, the demand for rapid tests continues to grow.

How Are Technological Advancements Enhancing the Accuracy and Accessibility of Rapid Tests?

Technological advancements are significantly enhancing the accuracy, sensitivity, and accessibility of rapid tests, making them more reliable and widely available for various diagnostic applications. The development of molecular diagnostics, such as PCR-based rapid tests, has greatly improved the sensitivity and specificity of pathogen detection, enabling the identification of diseases at an early stage. Advances in immunoassay technology have also contributed to the improved accuracy of rapid tests by allowing the detection of minute quantities of antigens or antibodies in patient samples. The miniaturization and integration of diagnostic platforms with digital technologies have further expanded the reach of rapid tests, enabling their use in remote and resource-limited settings. Additionally, the rise of point-of-care testing devices has brought rapid diagnostics closer to patients, reducing the need for centralized laboratories and enabling real-time decision-making in clinics, pharmacies, and even homes. These technological innovations are driving the widespread adoption of rapid tests in healthcare systems worldwide.

What Are the Key Applications and Benefits of Rapid Tests in Healthcare?

Rapid tests are used in a wide range of healthcare applications, offering significant benefits that improve patient outcomes, streamline workflows, and reduce healthcare costs. In infectious disease diagnostics, rapid tests enable the quick identification of pathogens, allowing for the immediate implementation of treatment and infection control measures. In emergency care settings, rapid tests provide critical information on a patient's condition, such as cardiac biomarkers or blood glucose levels, enabling timely interventions that can save lives. Rapid tests are also valuable in screening programs, such as HIV or hepatitis testing, where they facilitate early detection and linkage to care. Additionally, rapid tests are used in chronic disease management, where they provide real-time data on a patient's health status, allowing for more personalized and proactive care. The primary benefits of rapid tests include their speed, ease of use, and ability to provide accurate results without the need for specialized equipment or extensive training. These advantages make rapid tests essential tools in modern healthcare, supporting timely and effective patient care.

What Factors Are Driving the Growth in the Rapid Tests Market?

The growth in the Rapid Tests market is driven by several factors. The increasing prevalence of infectious diseases and the need for quick and accurate diagnostics are significant drivers, as healthcare systems seek to contain outbreaks and provide timely treatment. Technological advancements in molecular diagnostics, immunoassays, and point-of-care testing are also propelling market growth by improving the accuracy, sensitivity, and accessibility of rapid tests. The rising demand for decentralized and patient-centered care is further boosting the adoption of rapid tests, as these tools enable real-time diagnostics in various healthcare settings, including clinics, pharmacies, and homes. Additionally, the expansion of screening programs and the growing focus on preventive healthcare are contributing to market growth, as rapid tests play a crucial role in early detection and monitoring of diseases. These factors, combined with continuous innovation in diagnostic technology, are driving the sustained growth of the Rapid Tests market.

SCOPE OF STUDY:

The report analyzes the Rapid Tests market by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Instruments Offering, Consumables Offering, Other Offerings); Technology (Immunoassay Technology, Molecular Diagnostics Technology, Other Technologies); Application (Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • ALS Ltd.
  • AsureQuality Ltd.
  • Bureau Veritas SA
  • Eurofins Scientific SE
  • Genetic ID NA, Inc.
  • Intertek Group PLC
  • Merieux NutriSciences Corporation
  • Microbac Laboratories, Inc.
  • Omic USA Inc.
  • Romer Labs, Inc.
  • SGS SA
  • Tuv Sud AG

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Product Code: MG14353

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Impact of COVID-19 Pandemic and a Looming Global Recession
    • An Introduction to Rapid Tests
    • Global Market Outlook
    • Pathogens Emerges as the Largest Category
    • PCR-based Tests Segment Leads the Global Market
    • Meat & Seafood Products: The Largest Type of Food Tested
    • Rapid Tests - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 38 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Threat of Food Contamination Gives Rise to Increase Demand for Rapid Tests
    • Strict Regulatory Measures to Ensure Safety of Food Products Augurs Well for the Market
    • Advent of New and Effective Rapid Testing Technologies to Boost Market Prospects
    • Globalized Food Trade & Complex Food Supply Chains Give Rise to the Need for Rapid Tests
    • Rise in Foodborne Illnesses due to Contaminated Meat Products Necessitates Rapid Testing of Meat & Seafood
    • GMO Food Testing: Strict Regulatory Guidelines in Several Regions Drives Growth
    • PCR-based Rapid Food Tests
    • Rapid Microbiological Tests in Food & Beverages: Health Growth in Store
    • Innovations & Advancements in Rapid Food Tests
    • Market Restraints
    • Rising Demand for Point-of-Care Diagnostics Propels Market Growth
    • Increasing Use in Infectious Disease Detection Expands Addressable Market Opportunity
    • Technological Advancements in Rapid Testing Kits Strengthen Market Position
    • Growing Focus on Early Disease Detection and Prevention Drives Adoption of Rapid Tests
    • Surge in Demand for At-Home Testing Solutions Generates New Opportunities
    • Development of Multi-Parameter and Comprehensive Test Kits Sustains Market Growth
    • Expanding Applications in Pregnancy and Fertility Testing Throws Spotlight on Market Potential
    • Growth in Screening and Surveillance Programs Spurs Demand for Rapid Tests
    • Rising Adoption of Rapid Tests in Veterinary Diagnostics Propels Market Expansion
    • Growing Awareness of the Benefits of Rapid Testing in Reducing Healthcare Costs Drives Market Adoption
    • Innovations in Mobile and Digital Rapid Test Solutions Generate New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 2: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 3: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 4: World Rapid Tests Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Rapid Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Instruments Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Instruments Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Consumables Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Consumables Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Consumables Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Offerings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Other Offerings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Other Offerings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Immunoassay Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Molecular Diagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Molecular Diagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Molecular Diagnostics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Respiratory Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Respiratory Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Respiratory Tract Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Sexually Transmitted Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Sexually Transmitted Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Sexually Transmitted Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Antibiotic-Resistant Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Antibiotic-Resistant Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Antibiotic-Resistant Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Gastrointestinal Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Gastrointestinal Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Gastrointestinal Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Sepsis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Sepsis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Sepsis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 41: World Recent Past, Current & Future Analysis for Tropical & Vector-borne Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 42: World Historic Review for Tropical & Vector-borne Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: World 13-Year Perspective for Tropical & Vector-borne Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 44: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 45: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: World 13-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 47: World Recent Past, Current & Future Analysis for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 48: World Historic Review for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: World 13-Year Perspective for Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 50: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 51: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: USA Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: USA 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 56: USA Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: USA Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: USA 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 59: USA Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: USA Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: USA 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 62: USA Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: USA Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: USA 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Canada Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: Canada 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Canada Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Canada 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Canada Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Canada 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Canada Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Canada 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • JAPAN
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Japan Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Japan 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Japan Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: Japan 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Japan Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: Japan 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Japan Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: Japan 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • CHINA
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: China Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: China 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 92: China Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: China Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: China 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 95: China Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: China Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: China 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 98: China Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: China Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: China 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • EUROPE
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Europe Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Europe 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Europe Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Europe 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Rapid Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 108: Europe Historic Review for Rapid Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Europe 13-Year Perspective for Rapid Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Europe Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: Europe 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: Europe Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: Europe 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • FRANCE
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 116: France Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: France Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: France 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 119: France Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: France Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: France 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 122: France Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: France Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: France 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 125: France Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: France Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: France 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • GERMANY
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Germany Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Germany 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Germany Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Germany 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Germany Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Germany 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Germany Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Germany 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Italy Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Italy 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Italy Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Italy 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Italy Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Italy 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Italy Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Italy 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 152: UK Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: UK Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: UK 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 155: UK Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: UK Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: UK 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 158: UK Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: UK Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: UK 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 161: UK Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: UK Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: UK 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Spain Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Spain 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Spain Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Spain 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Spain Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Spain 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Spain Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Spain 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Russia Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: Russia 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Russia Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Russia 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Russia Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Russia 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Russia Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Russia 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Europe 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Rest of Europe 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Rest of Europe 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Rest of Europe 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Rapid Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Rapid Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Asia-Pacific 13-Year Perspective for Rapid Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Asia-Pacific 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Asia-Pacific 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Asia-Pacific 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Asia-Pacific 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Australia Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Australia 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Australia Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Australia 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Australia Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Australia 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Australia Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Australia 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • INDIA
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 227: India Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: India Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: India 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 230: India Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: India Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: India 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 233: India Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: India Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: India 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 236: India Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: India Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: India 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: South Korea Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: South Korea 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: South Korea Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: South Korea 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: South Korea Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: South Korea 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: South Korea Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: South Korea 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Latin America Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Latin America 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Latin America Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Latin America 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Rapid Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 270: Latin America Historic Review for Rapid Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Latin America 13-Year Perspective for Rapid Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Latin America Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Latin America 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Latin America Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Latin America 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Argentina Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Argentina 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Argentina Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: Argentina 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: Argentina Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: Argentina 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Argentina Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: Argentina 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Brazil Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: Brazil 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Brazil Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Brazil 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Brazil Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Brazil 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Brazil Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Brazil 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Mexico Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Mexico 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Mexico Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: Mexico 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Mexico Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 310: Mexico 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 312: Mexico Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 313: Mexico 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 316: Rest of Latin America 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Rapid Tests by Application - Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 319: Rest of Latin America 13-Year Perspective for Rapid Tests by Application - Percentage Breakdown of Value Sales for Respiratory Tract Infections Application, Sexually Transmitted Infections Application, Antibiotic-Resistant Infections Application, Gastrointestinal Infections Application, Sepsis Application, Tropical & Vector-borne Diseases Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Rapid Tests by Offering - Instruments Offering, Consumables Offering and Other Offerings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 322: Rest of Latin America 13-Year Perspective for Rapid Tests by Offering - Percentage Breakdown of Value Sales for Instruments Offering, Consumables Offering and Other Offerings for the Years 2020, 2026 & 2032
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Rapid Tests by End-Use - Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 325: Rest of Latin America 13-Year Perspective for Rapid Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Laboratories End-Use and Other End-Uses for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Rapid Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 327: Middle East Historic Review for Rapid Tests by Technology - Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 328: Middle East 13-Year Perspective for Rapid Tests by Technology - Percentage Breakdown of Value Sales for Immunoassay Technology, Molecular Diagnostics Technology and Other Technologies for the Years 2020, 2026 & 2032
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!